Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease - PACE-CME

Hopeful results with SGLT inhibitor in patients with TDM and chronic kidney disease

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
AHA 2024
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD
MinuteCE®
Optimizing care for patients with CKM syndrome: a multidisciplinary approach
1.00 credit 4 episodes
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Jürgen Floege, MD
- Muthiah Vaduganathan, MD, MPH
1.00 credit 4 episodes
Effects of empaglifozin on kidney outcomes after acute MI
Effects of empaglifozin on kidney outcomes after acute MI
ESC Congress 2024
Effects of empaglifozin on kidney outcomes after acute MI
- Deepak Bhatt, MD